Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 617
Aptamer sequence: GTACCAGCTTATTCAATTACACGGACAGAGGGTAGCGGCTCTGCGCATTGAGTTGCTGCGGGCTGAAGCGCGGTACATGGGAGATAGTATGTTCATCAG
Target unique ID: 221493
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_584 11 Molecule Cholic acid 52.1 μM 50 mM Tris-HCl, 300 mM NaCl, 30 mM KCl, 5 mM MgCl2, pH 7.6 10978501
Structure information of aptamer
Aptamer Sequence: GTACCAGCTTATTCAATTACACGGACAGAGGGTAGCGGCTCTGCGCATTGAGTTGCTGCGGGCTGAAGCGCGGTACATGGGAGATAGTATGTTCATCAG
The optimal secondary structure in dot-bracket notation: (((((.((((...............(((...((((((((((........))))))))))...)))))))..)))))...((.((........)).))..
The centroid secondary structure in dot-bracket notation: (((((.((((...(........)..(((...((((((((((........))))))))))...)))))))..))))).......................
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_584 Description 11
Aptamer chemistry DNA Length 99 nt
GC content 52.5% Molecular weight 30,760.66 Da
Molarity of 1 μg/μl solution 32.51 μM Number of G-quadruplexes No QGRS found
G-Score N/A Function Aptasensor
Sequence GTACCAGCTTATTCAATTACACGGACAGAGGGTAGCGGCTCTGCGCATTGAGTTGCTGCGGGCTGAAGCGCGGTACATGGGAGATAGTATGTTCATCAG
Applications Recognition of cholic acid
Target information
Type Detail Type Detail
PubChem ID 221493 Molecular name Cholic acid
Molecular formula C24H40O5 Molecular weight 408.6
IUPAC name (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid InChIKey BHQCQFFYRZLCQQ-OELDTZBJSA-N
LogP 3.449 Topological polar surface area 97.99
Hydrogen bond acceptor 4 Hydrogen bond donor 4

Synonym(s):
cholic acid; 81-25-4; cholate; Colalin; Cholalic acid; Cholalin; Cholsaeure; Cholbam; NSC-6135; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; Cholic acid, 5beta-; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; SODIUM CHOLATE; UNII-G1JO7801AE; MFCD00003672; HSDB 982; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; Cholic acid [USAN]; 3,7,12-Trihydroxycholanic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3a,5b,7a,12a)-; TERPENES AND TERPENOIDS; CHEMBL205596; G1JO7801AE; CHEBI:16359; NSC6135; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanate; CHD; Cholic acid (USAN); 3-alpha,7-alpha,12-alpha-Trihydroxy-5-beta-cholan-24-oic acid; 5beta-Cholan-24-oic acid, 3alpha,7alpha,12alpha-trihydroxy-; C24H40O5; 3,7,12-Trihydroxycholan-24-oic acid, (3alpha,5beta,7alpha,12alpha)-; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3alpha,7alpha,12alpha-triol; 3,7,12-Trihydroxy-cholan-24-oic acid (3-alpha,5-beta,7-alpha,12-alpha); Cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)-; 129874-08-4; 4-[(3R,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; kolbam; (3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxycholan-24-oic acid; (3alpha,5beta,7alpha,8x,12alpha)-3,7,12-trihydroxycholan-24-oic acid; SMR000112165; Colalin (VAN); Cholsaeure [German]; 5beta-Cholanic acid-3alpha,7alpha,12alpha-triol; Cholalate; OrphacolReg; cholic-acid; CCRIS 1626; (3alpha,5beta,7alpha,8xi,12alpha)-3,7,12-trihydroxycholan-24-oic acid; 5b-Cholate; 5b-Cholic acid; CholsA currencyure; Cholbam (TN); EINECS 201-337-8; Cholic acid (8CI); 5.beta.-Cholic acid; BRN 2822009; 361-09-1; Spectrum5_002005; 3alpha,7alpha,12alpha-Trihydroxycholanic acid; bmse000650; EC 201-337-8; 3-alpha,7-alpha,12-alpha-Trihydroxycholansaeure; BIDD:PXR0196; SCHEMBL27461; GTPL609; 3.alpha.,7.alpha.,12.alpha.-Trihydroxy-5.beta.-cholanic acid; 4-10-00-02072 (Beilstein Handbook Reference); MLS001066422; MLS002207051; 3a,7a,12a-Trihydroxycholanate; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanoic acid; DTXSID6040660; BDBM21680; 3-alpha,7-alpha,12-alpha-Trihydroxycholansaeure [German]; HMS2268L18; 3a,7a,12a-Trihydroxy-b-cholanate; 3a,7a,12a-Trihydroxycholanic acid; HY-N0324; ZINC6858022; 3a,7a,12a-Trihydroxy-5b-cholanate; 5b-Cholanic acid-3a,7a,12a-triol; BBL029799; LMST04010001; s3742; STK801993; 3a,7a,12a-Trihydroxy-5b-cholanoate; 3a,7a,12a-Trihydroxy-beta-cholanate; AKOS005622502; 3a,7a,12a-Trihydroxy-b-cholanic acid; CCG-268746; CS-6608; DB02659; MCULE-7032345049; 3a,7a,12a-Trihydroxy-5A-cholanic acid; 3a,7a,12a-Trihydroxy-5b-cholanic acid; NCGC00142384-03; 3a,7a,12a-Trihydroxy-5b-cholanoic acid; 3a,7a,12a-Trihydroxy-beta-cholanic acid; 4-((1S,2S,7S,11S,16S,5R,9R,10R,14R,15R)-5,9,16-trihydroxy-2,15-dimethyltetracy clo[8.7.0.0<2,7>.0<11,15>]heptadec-14-yl)pentanoic acid; AS-69849; BP-30084; K446; 3?,7?,12?-Trihydroxy-5?-cholanic acid; 3a,7a,12a-Trihydroxy-5b-cholan-24-oate; Cholic acid, Vetec(TM) reagent grade, 98%; N1680; Cholic acid, from ox or sheep bile, >=98%; 3a,7a,12a-Trihydroxy-5b-cholan-24-oic acid; 7060-EP2289879A1; 7060-EP2289883A1; 7060-EP2315303A1; C-5900; C00695; D10699; 198976-EP2280282A1; A830252; Q287415; SR-01000765698; 3alpha,7alpha,12alpha-Trihydroxy-beta-cholanic acid; SR-01000765698-4; 3.alpha.,12.alpha.-Trihydroxy-5.beta.-cholanic acid; 3-.alpha.,7-.alpha.,12-.alpha.-Trihydroxycholansaeure; 3alpha, 7alpha, 12alpha-trihydroxy-5beta-cholanic acid; 3alpha, 7alpha, 12alpha-trihydroxy-5beta-cholanoic acid; 3-&alpha,7-&alpha,12-&alpha-trihydroxy-5-&beta-cholanate; Cholic acid, British Pharmacopoeia (BP) Reference Standard; Cholic acid, European Pharmacopoeia (EP) Reference Standard; UNII-JIY1ILR284 component BHQCQFFYRZLCQQ-OELDTZBJSA-N; 17b-[1-Methyl-3-carboxypropyl]etiocholane-3a,7a,12a-triol; 5.beta.-Cholan-24-oic acid,7.alpha.,12.alpha.-trihydroxy-; 5beta-Cholanic acid, 3alpha,7alpha,12alpha-trihydroxy- (7CI); 5beta-Cholanic acid-3alpha,7alpha,12alpha-triol 5beta-Cholic acid; Cholic acid, 500 mug/mL in methanol, certified reference material; Cholic acid, United States Pharmacopeia (USP) Reference Standard; 17beta-[1-Methyl-3-carboxypropyl]etiocholane-3alpha,7alpha,12alpha-triol; 3-.alpha.,7-.alpha.,12-.alpha.-Trihydroxy-5-.beta.-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic Acid (Cholic Acid); 5.beta.-Cholan-24-oic acid, 3.alpha.,7.alpha.,12.alpha.-trihydroxy-; (3.alpha.,5.beta.,7.alpha.,12.alpha.)-3,7,12-Trihydroxycholan-24-oic acid sodium salt; (3alpha,5beta,7alpha,8alpha,12alpha,14beta,17alpha)-3,7,12-trihydroxycholan-24-oic acid; 17.beta.-(1-Methyl-3-carboxypropyl)etiocholane-3.alpha.,7.alpha.,12.alpha.-triol; 3,7,12-Trihydroxy-cholan-24-oic acid, (3.alpha.,5.beta.,7.alpha.,12.alpha.)-; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3-alpha,5-beta,7-alpha,12-alpha)-; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3-alpha,5-beta,7-alpha,12-alpha)- (9CI); Cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)- (9CI); Cholan-24-oic acid,7,12-trihydroxy-, (3.alpha.,5.beta.,7.alpha.,12.alpha.)-; (4R)-4-((3R,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; (4R)-4-[(1R,3aS,3bR,4R,5aS,7R,9aS,9bS,11S,11aR)-4,7,11-trihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanoic acid; (4R)-4-[(1S,2S,5R,7S,9R,10R,11S,14R,15R,16S)-5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic acid; (R)-4-((3R,5S,7R,8R,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; 10321-98-9

Activity data

No relevant experimental diagram

 Interaction ID 617
Target type Molecule
Target unique ID 221493
Activity 52.1 μM
Binding Conditions/Buffer

50 mM Tris-HCl, 300 mM NaCl, 30 mM KCl, 5 mM MgCl2, pH 7.6
Assay

N/A
PubMed ID 10978501
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_581 DNA GTACCAGCTTATTCAATTCGCGGAAGACGAATTCCAAGCGCGCGCGGGTCACGCGACTTGGGAATGAGCAAGGGTTGGCCCGAGATAGTATGTTCATCAG 66.00%
Apta_582 DNA GTACCAGCTTATTCAATTGGGCGAAGGAACATACGGCAGTTTATGGCCGCTATCGAGATAGACTATCATCTCAACGTCTTCTAGATAGTATGTTCATCAG 64.00%
Apta_583 DNA GTACCAGCTTATTCAATTGCGAGCAGGGTCAATGGAATTAATGATCAATTGACAGACGCAAGTCTCCTGCGGTCCTGTGTTGAGATAGTATGTTCATCAG 64.00%
Apta_628 DNA ATACCAGCTTATTCAATTAGCCCGGTATTGAGGTCGATCTCTTATCCTATGGCTTGTCCCCCATGGCTCGGTTATATCCAGATAGTAAGTGCAATCT 62.63%
Apta_628 DNA ATACCAGCTTATTCAATTAGCCCGGTATTGAGGTCGATCTCTTATCCTATGGCTTGTCCCCCATGGCTCGGTTATATCCAGATAGTAAGTGCAATCT 62.63%
Apta_627 DNA ATACCAGCTTATTCAATTATGCGGGGATGAGGCTTGATCTGTGGCTCTGATCCATGATCAGTCGTCTTACGTGCGGTCCAGATAGTAAGTGCAATCT 61.62%
Apta_627 DNA ATACCAGCTTATTCAATTATGCGGGGATGAGGCTTGATCTGTGGCTCTGATCCATGATCAGTCGTCTTACGTGCGGTCCAGATAGTAAGTGCAATCT 61.62%
Apta_727 DNA ATACCAGCTTATTCAATTAGTCACACTTAGAGTTCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGATAGTAAGTGCAATCT 60.61%
Apta_1016 DNA ATACCAGCTTATTCAATTTCTTCGCCAGTGCCAGGATCTCAGTTGGCGGTTCATTAGCTGGGTTGGTCGAAGATAGTAAGTGCAATCT 60.61%
Apta_451 DNA ATACCAGCTTATTCAATTGAGTAAGAGTGCACTATGTTTTACGAGCCGTTTCCTCGGCAGATAGTAAGTGCAATCT 59.60%
Apta_805 DNA ATACCAGCTTATTCAATTAGGCGGTGCATTGTGGTTGGTAGTATACATGAGGTTTGGTTGAGACTAGTCGCAAGATATAGATAGTAAGTGCAATCT 59.60%
Apta_1015 DNA ATACCAGCTTATTCAATTGACCCGTTTCGTTCCCTCTGGGAAGTTTAGCCCAGTTGCCTGGGCGATACCAAGATAGTAAGTGCAATCT 59.60%
Apta_349 DNA ATACCAGCTTATTCAATTAGACGAGTTTTATTCATTTTCCATGTCGTAGCTTACCGTGAGATAGTAAGTGCAATCT 58.59%
Apta_625 DNA ATACCAGCTTATTCAATTCAGGGCGGTATGAGGCTCGATCAAGGTCGGAGCGAGAATTTTTTCGCGGAGTCGGCTGGATCAGATAGTAAGTGCAATCT 58.59%
Apta_625 DNA ATACCAGCTTATTCAATTCAGGGCGGTATGAGGCTCGATCAAGGTCGGAGCGAGAATTTTTTCGCGGAGTCGGCTGGATCAGATAGTAAGTGCAATCT 58.59%
Apta_354 DNA ATACCAGCTTATTCAATTCTATACTCCACTTTGCTATTTCTCGGTTCCTTCACGCGCCGATCGCAGGCTGATGAATTGAGATAGTAAGTGCAATCT 57.58%
Apta_450 DNA ATACCAGCTTATTCAATTACATGTCCTGAAGGGGAATAATATACAGCTTTGGGTGGGTAGATAGTAAGTGCAATCT 57.58%
Apta_626 DNA ATACCAGCTTATTCAATTGGTGGTAGGATGGGCTCGATCGAGGTCTTCAGTCGGCTCGGTTTAGTTTATGTTCTCCTGTAGATAGTAAGTGCAATCT 56.57%
Apta_792 DNA ATACCAGCTTATTCAATTCCCAAATTGCCACCACTTACAGCATGATAACATACTACATCTTTTCATCAAGATAGTAAGTGCAATCT 56.57%
Apta_1217 DNA ATACGAGCTTGTTCAATACGAAGGGATGCCGTTTGGGCCCAAGTTCGGCATAGTGTGGTGATAGTAAGAGCAATC 56.57%

ABOUT

AptaDB is an online database we developed to integrate comprehensive information about aptamer.
The detail of this database is described here:

HELP CENTER

>Contact us
>LMMD Group
>School of Pharmacy

DEV TOOL
Page last updated at 2022-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 43973
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.